drugset
drugset / Trial / NCT03494504

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504 ↗

Phase 3 Completed 318 enrolled Aldeyra Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis

Timeline

Start
2018-03-30
Primary completion
2018-11-05
Completion
2018-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 % —
Subject Reproxalap Other / unclassified 0.5 % —

Indications

conjunctivitis